HC Wainwright Has Positive View of Annovis Bio Q2 Earnings

Annovis Bio, Inc. (NYSE:ANVS - Free Report) - Stock analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for Annovis Bio in a research note issued on Monday, June 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.36) for the quarter, up from their prior forecast of ($0.49). HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Annovis Bio's current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio's Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.45) EPS and FY2025 earnings at ($1.52) EPS.

Separately, Canaccord Genuity Group lowered their target price on shares of Annovis Bio from $26.00 to $17.00 and set a "buy" rating on the stock in a report on Thursday, May 15th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $30.25.

Annovis Bio Stock Performance

ANVS traded up $0.10 during trading on Wednesday, hitting $2.90. The stock had a trading volume of 179,556 shares, compared to its average volume of 737,579. The firm has a market capitalization of $56.51 million, a P/E ratio of -0.65 and a beta of 1.62. Annovis Bio has a twelve month low of $1.11 and a twelve month high of $17.88. The company's 50-day moving average price is $1.83 and its 200 day moving average price is $3.10.

Annovis Bio (NYSE:ANVS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.47) by $0.15.

Institutional Investors Weigh In On Annovis Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC grew its stake in shares of Annovis Bio by 99.7% during the 4th quarter. Jane Street Group LLC now owns 68,107 shares of the company's stock worth $343,000 after purchasing an additional 34,001 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Annovis Bio during the 4th quarter worth $258,000. Warberg Asset Management LLC purchased a new stake in shares of Annovis Bio in the 1st quarter worth about $58,000. Northern Trust Corp boosted its position in shares of Annovis Bio by 49.4% in the 4th quarter. Northern Trust Corp now owns 32,780 shares of the company's stock worth $165,000 after buying an additional 10,846 shares in the last quarter. Finally, Greenwich Wealth Management LLC grew its stake in Annovis Bio by 93.9% in the 4th quarter. Greenwich Wealth Management LLC now owns 31,951 shares of the company's stock valued at $161,000 after acquiring an additional 15,476 shares during the last quarter. Institutional investors and hedge funds own 15.83% of the company's stock.

About Annovis Bio

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.